| INTRODUC TI ONIn a recent study, Hu et al 1 reported that plasma long pentraxin-3 (PTX-3), a sensitive inflammatory marker, decreased after following a low-sodium diet and increased after high-sodium intake, and that potassium supplementation inhibited the salt-induced increase of PTX-3. The responses of PTX-3 to dietary interventions were more evident in salt-sensitive than salt-resistant subjects. The study showed the possible implications of high-sodium intake in cardiovascular risk and the attenuation of PTX-3 responses by potassium supplementation.The role of PTX-3 in inflammation is still debated. PTX-3 shares structural homology with short pentraxins as C-reactive protein (CRP). 2In particular, it is still not clear whether PTX-3 is a protective or a proinflammatory cytokine. CRP is mainly produced by hepatocytes, while PTX-3 is produced by several tissues and in particular by macrophages and T lymphocytes that are the mediators of inflammatory reaction. 3 Sodium and potassium are important constituents of the human body, and many studies have reported that high-sodium intake and/ or salt sensitivity can be involved in hypertension and cardiovascular risk. 4 Sodium sensitivity is an individual marker that is linked to genetics-for example, African Americans are frequently sodium sensitive and show a higher risk for developing low-renin essential hypertension. 5 In the recent years, the involvement of inflammation in hypertension and its complications has been extensively evaluated. Inflammation can be linked to high-sodium intake or an excess of aldosterone, increasing local and systemic inflammatory reaction mediated by T cells and macrophages. 6
| REL ATI ON S HIP B E T WEEN SOD I UM AND THE RENIN -ANG I OTEN S IN -ALDOS TERONE SYS TEMThe suppression of the renin angiotensin aldosterone system (RAAS) is a mechanism of defense against major damages in patients with sodium retention and volume expansion. Many studies have focused on the relationship between aldosterone, sodium, and cardiovascular risk using the animal model of non-nephrectomized rats associated with sodium and aldosterone administration. 7 A clinical situation of sodium retention and an increase of aldosterone is only present in primary aldosteronism (PA) or other forms of mineralocorticoid-related hypertension. This animal model is not useful to investigate other forms of hypertension since the retention of sodium or sodium supplementation are associated with suppression of the RAAS. The involvement of aldosterone in inflammation and cardiovascular risk is proven by the studies of Pitt et al, evaluating the significant reduction of cardiovascular risk in patients treated with spironolactone or eplerenone. 8,9 Aldosterone receptor blockers are effective even in patients with normal values of renin and aldosterone and also in sodium depleted subjects treated with thiazide diuretics. 10 A recent paper by Mulatero et al 11 reported a clear decrease in cardiovascular risk in patients with idiopathic PA during treatment with aldosterone recep...